In a letter submitted July 2 to the Centers for Medicare & Medicaid Services on guidance for the Medicare Drug Price Negotiation Program, the AHA expressed concern about the agency’s proposal to retrospectively effectuate the policy.

The AHA called CMS’ retrospective refund process “complex, burdensome and would be operationally unworkable,” and could unwillingly cause providers to pursue rebates and 340B discounts from drug manufacturers instead of requiring them to make lower negotiated prices available upfront. The AHA urged CMS to finalize a prospective process that aligns with the Health Resources and Services Administration’s historic interpretation of the 340B statutory requirements and balances the interests of Medicare patients, dispensing entities and manufacturers under the program.

Related News Articles

Headline
The AHA today voiced support for the Rural Hospital Support Act (S. 335), legislation that would make the Medicare-dependent Hospital program and low-volume…
Headline
The AHA Jan. 31 commended Sens. Bill Cassidy, R-La., Catherine Cortez Masto, D-Nev., John Cornyn, R-Texas., and Michael Bennet, D-Colo., on draft legislation…
Headline
The White House Office of Management and Budget Jan. 29 rescinded a memo it issued two days earlier directing federal agencies to temporarily pause federal…
Headline
An analysis by KFF released Jan. 28 found that Medicare Advantage insurers made nearly 50 million prior authorization determinations in 2023. The finding…
Headline
The White House Office of Management and Budget late Jan. 27 issued a memo directing federal agencies to temporarily pause federal grants, loans and other…
Headline
The AHA Jan. 27 voiced support for the Centers for Medicare & Medicaid Services proposed rule on policy and technical changes to Medicare Advantage and…